Skip to main content
drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (NK cells)
drug_description
Adoptive natural killer (NK) cell therapy intended to eliminate HER2-expressing tumor cells via NK-mediated cytotoxicity; used as a cellular immunotherapy.
nci_thesaurus_concept_id
C69129
nci_thesaurus_definition
An 85-amino acid recombinant peptide derived from protein c2 of the hemophagocytic hookworm Ancylostoma caninum (a common canine parasite) with anticoagulant activity. Anpocogin binds to circulating activated factor X (FXa) or zymogen factor X (FX) to form a binary complex which subsequently binds to and inhibits membrane-bound activated factor VII/tissue factor complex (FVIIa/TF). When administered prophylactically, this agent may reduce the incidence of deep venous thrombosis without hemostatic compromise. Because rNAPc2 inhibits the formation of the FVIIa/TF protease complex, which may play a role in the cellular signaling of both metastatic and angiogenic processes, it may impede tumor progression.
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptive transfer of ex vivo expanded natural killer (NK) cells designed to recognize and eliminate HER2-expressing tumor cells via NK-mediated cytotoxicity (perforin/granzyme and death-receptor pathways), with lymphodepletion used to enhance NK-cell engraftment and persistence.
drug_name
AB-201
nct_id_drug_ref
NCT05678205